Pacira BioSciences (PCRX) Expected to Announce Earnings on Thursday

Pacira BioSciences (NASDAQ:PCRX) will likely be releasing its Q1 2025 earnings data after the market closes on Thursday, May 8th. Analysts expect Pacira BioSciences to post earnings of $0.61 per share and revenue of $176.35 million for the quarter.

Pacira BioSciences Price Performance

Shares of NASDAQ PCRX opened at $25.81 on Tuesday. The business’s 50 day moving average is $24.65 and its 200-day moving average is $21.95. The firm has a market cap of $1.19 billion, a P/E ratio of -12.71 and a beta of 0.56. Pacira BioSciences has a 1-year low of $11.16 and a 1-year high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Barclays raised their target price on Pacira BioSciences from $17.00 to $24.00 and gave the company an “overweight” rating in a report on Friday, February 28th. Needham & Company LLC restated a “buy” rating and set a $32.00 price target on shares of Pacira BioSciences in a report on Tuesday, April 8th. Royal Bank of Canada reiterated a “sector perform” rating and issued a $18.00 price objective on shares of Pacira BioSciences in a report on Tuesday, January 14th. Truist Financial raised shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their price objective for the stock from $8.00 to $25.00 in a research note on Thursday, January 30th. Finally, HC Wainwright raised their price objective on Pacira BioSciences from $48.00 to $65.00 and gave the stock a “buy” rating in a research report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average target price of $26.67.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.